NS INVESTMENT
NS Investment (NSI) is an affiliated firm of Dong-A ST, a leading pharmaceutical company in the Republic of Korea. NSI was established in 2015 to independently manage venture capital funds and serve institutional investors in Korea. NSI is focused on meeting the financial objective of its fund investors. NSI seeks to link Korean investor capital with innovative companies beyond its domestic boarders and ultimately link entrepreneurs and science across continents.
NS INVESTMENT
Founded:
2016-01-01
Status:
Active
Technology used in webpage:
Content Delivery Network Google Apps For Business JsDelivr PHP 7 JQuery CDN
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-25 | Aktis Oncology | NS Investment investment in Series A - Aktis Oncology | 84 M USD |
| 2022-05-09 | Aspen Neuroscience | NS Investment investment in Series B - Aspen Neuroscience | 147.5 M USD |
| 2022-02-03 | Dewpoint Therapeutics | NS Investment investment in Series C - Dewpoint Therapeutics | 150 M USD |
| 2022-01-10 | Maze Therapeutics | NS Investment investment in Venture Round - Maze Therapeutics | 190 M USD |
| 2021-11-02 | Shoreline Biosciences | NS Investment investment in Series B - Shoreline Biosciences | 140 M USD |
| 2021-10-21 | ReCode Therapeutics | NS Investment investment in Series B - ReCode Therapeutics | 80 M USD |
| 2021-08-18 | Immunitas Therapeutics | NS Investment investment in Series B - Immunitas Therapeutics | 58 M USD |
| 2021-08-04 | Sonoma BioTherapeutics | NS Investment investment in Series B - Sonoma BioTherapeutics | 265 M USD |
| 2020-04-23 | Accent Therapeutics | NS Investment investment in Series B - Accent Therapeutics | 63 M USD |
| 2020-03-11 | Silverback Therapeutics | NS Investment investment in Series B - Silverback Therapeutics | 78.5 M USD |